SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 2,601 Shares of Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 2,601 shares of SiBone stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $18.33, for a total value of $47,676.33. Following the completion of the transaction, the chief financial officer owned 208,533 shares in the company, valued at $3,822,409.89. This trade represents a 1.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The shares were sold at an average price of $14.20, for a total value of $47,016.20.
• On Monday, August 18th, Anshul Maheshwari sold 3,461 shares of SiBone stock. The shares were sold at an average price of $15.57, for a total transaction of $53,887.77.

SiBone Trading Down 0.8%

Shares of SiBone stock traded down $0.14 during trading hours on Friday, hitting $17.13. The company’s stock had a trading volume of 285,942 shares, compared to its average volume of 434,386. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05. The company has a market capitalization of $743.05 million, a PE ratio of -33.57 and a beta of 0.81. The company has a quick ratio of 7.00, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The business has a fifty day moving average of $15.30 and a 200 day moving average of $16.60.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. SiBone has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that SiBone will post -0.78 EPS for the current year.

Institutional Investors Weigh In On SiBone

Institutional investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone during the first quarter valued at approximately $34,000. State of Alaska Department of Revenue purchased a new position in SiBone in the third quarter worth about $39,000. State of Wyoming bought a new stake in shares of SiBone during the 2nd quarter worth approximately $55,000. Virtus Advisers LLC bought a new stake in shares of SiBone in the 1st quarter valued at about $58,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of SiBone during the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Truist Financial decreased their price target on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an “overweight” rating in a research note on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SiBone has an average rating of “Moderate Buy” and an average price target of $23.00.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.